gt719
Cell therapyexperimental
Clinical trial activity
5 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Sep 25, 2024 (NCT07131254)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- B-lymphocyte antigen CD19Immunity, passive
CD19 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07132112 | Early Phase 1 (Phase 1) | Aug 31, 2025 | Grit Biotechnology, Nantong University |
| NCT07122076 | Early Phase 1 (Phase 1) | Aug 22, 2025 | Grit Biotechnology |
| NCT06948981 | Phase 1/Phase 2 (Phase 2) | Apr 18, 2025 | China Academy of Chinese Medical Sciences, Grit Biotechnology |
| NCT07021209 | Phase 1 | Jan 14, 2025 | Grit Biotechnology, Huazhong University of Science and Technology |
| NCT07131254 | Phase 1/Phase 2 (Phase 2) | Sep 25, 2024 | Ganzhou City People's Hospital, Grit Biotechnology |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Grit Biotechnology | For profit | 5 | 5 | 2 | 2024 |
| China Academy of Chinese Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Ganzhou City People's Hospital | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Nantong University | Academic/Hospital | 1 | 0 | 1 | 2025 |
5 organizations
Page 1 / 1